Actinium (NYSE: $ATNM)
Announces Pricing of Public Offering of Common Stock
NEW
YORK - September 29, 2016 (Investorideas.com Newswire) Actinium
Pharmaceuticals, Inc. (NYSE: ATNM)
("Actinium" or "the Company"), a biopharmaceutical Company
developing innovative targeted payload immunotherapeutics for the treatment of
advanced cancers, announced today the pricing of an underwritten public
offering of 8,000,000 shares of its common stock at a price to the public of
$1.25. In addition, Actinium has granted the underwriters a 30-day option to
purchase up to an additional 1,200,000 shares of common stock solely to cover
over-allotments, if any. The offering is expected to close on or about October
4, 2016, subject to customary closing conditions.
The
gross proceeds to Actinium from this offering is expected to be $10,000,000,
before deducting underwriting discounts and commissions and other estimated
offering expenses payable by Actinium. Actinium currently intends to use the
net proceeds from the sale of securities for general corporate purposes,
including capital expenditures, the advancement of its drug candidates in
clinical trials, such as Iomab™-B and Actimab™- A, preclinical trials, and to
meet working capital needs.
H.C.
Wainwright & Co. is acting as sole book-running manager for the offering.
JonesTrading Institutional Services LLC is acting as co-manager for the
offering. ROTH Capital is acting as a financial advisor for the offering.
The
offering is being conducted pursuant to a shelf registration statement that was
previously filed with, and declared effective by, the U.S. Securities and
Exchange Commission ("SEC"). Prospective investors should read in
their entirety the prospectus supplement and the accompanying prospectus and
the other documents that Actinium has filed with the SEC for more complete
information about Actinium and the offering. A prospectus supplement and
accompanying prospectus relating to the offering will be filed with the SEC and
will be available free of charge on the website of the SEC at www.sec.gov.
Electronic copies of the preliminary prospectus supplement and accompanying
prospectus and, when available, the prospectus supplement and the accompanying
prospectus may also be obtained from the offices of H.C. Wainwright & Co.,
LLC by emailing placements@hcwco.com.
This
press release shall not constitute an offer to sell or the solicitation of an
offer to buy any of the securities described herein, nor shall there be any
sale of these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of such state or jurisdiction.
About Actinium Pharmaceuticals
Actinium
Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical
company developing innovative targeted payload immunotherapeutics for the
treatment of advanced cancers. Actinium's targeted radioimmunotherapy products
are based on its proprietary delivery platform for the therapeutic utilization
of alpha-emitting Actinium-225 and Bismuth-213 and certain beta emitting
radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's
lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon
approval, in preparing patients for hematopoietic stem cell transplant,
commonly referred to as bone marrow transplant. The Company is conducting a
single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory or
relapsed AML patients over the age of 55 with a primary endpoint of durable
complete remission. The Company's second product candidate, Actimab-A, is in a
53 patient, multicenter, open-label Phase 2 trial for patients newly diagnosed
with AML over the age of 60 in a single-arm multicenter trial
Forward-Looking
Statements for Actinium Pharmaceuticals, Inc.
This
news release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. These statements are based on
management's current expectations and involve risks and uncertainties, which
may cause actual results to differ materially from those set forth in the
statements. The forward-looking statements may include statements regarding
product development, product potential, or financial performance. No
forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Actinium Pharmaceuticals undertakes no
obligation to publicly update any forward-looking statement, whether as a
result of new information, future events, or otherwise.
Contact:
Steve
O'Loughlin
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com
Vice President, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
soloughlin@actiniumpharma.com
Source:
Actinium Pharmaceuticals
This news is
published on the Investorideas.com Newswire - a global digital news source for
investors and business leaders
Sign up for free news alerts
Disclaimer/Disclosure:
Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info:http://www.investorideas.com/About/Disclaimer.asp.
Disclosure:
One month news , social media and marketing Actinium Pharmaceuticals, Inc.
(ATNM) by third party IRTH Communications starting September 19, 2016: three
thousand per month.
No comments:
Post a Comment